DexCom Inc
Most Recent
Could Brighthouse Financial Turn Around This Year?
The most significant contributors to Greenlight Capital’s (GLRE) gains last year included Micron Technology (MU) and Twitter (TWTR).
A $300 Billion Opportunity Is Waiting for Apple
In 2017, Apple (AAPL) was selected alongside Samsung (SSNLF), Fitbit (FIT), Alphabet’s (GOOGL) Verily, and others for a US Food and Drug Administration (or FDA) pilot program on digital health software certification.
The Biggest Detractors for Einhorn’s Greenlight in 2018
Overall, in 2018, the most significant contributors to Greenlight Capital’s gains included Micron Technology (MU) and Twitter (TWTR).
Why Alphabet’s Verily Sought External Funding
Alphabet’s (GOOGL) Verily subsidiary recently raised $1.0 billion in additional capital from a group of investors led by private equity firm Silver Lake.
Why Apple Might Be Hiring Doctors
Apple (AAPL) has been quietly recruiting doctors to join its staff, CNBC has reported, citing people familiar with the matter.
Why Tandem Diabetes Care Stock Soared Over 1,480% in 2018
Tandem Diabetes Care (TNDM) stock grew from $2.36 on December 29, 2017, to reach $37.31 at the close of market on December 28, 2018, an increase of ~1,481% this year.
A Closer Look at Dexcom Stock’s 117% Year-to-Date Growth
On November 23, Dexcom (DXCM) stock closed at $124.28, a rise of ~2.20% from its previous day’s close of $121.61.
Tandem Diabetes Care Stock Has Skyrocketed in 2018
On November 21, Tandem Diabetes Care stock closed at $32.63, a ~14.69% rise from its previous day’s close of $28.45.
Why Wall Street Is Still Bullish on Tandem Stock
This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating.
Why Tandem Should Be on Your Stock Radar
Tandem Diabetes Care’s (TNDM) key focus is its t:slim X2 insulin delivery system, which is designed to display continuous glucose monitoring directly on a pump’s home screen.
A Look into Johnson & Johnson’s Diabetes Care Business
In the US and international markets, Johnson & Johnson’s Diabetes Care segment generated third-quarter net revenues of $125.0 million and $190.0 million, respectively.
DexCom Has Reported 150% Growth in 2018 Year-to-Date
The stock of DexCom (DXCM) has risen 150%, from $57.99 on January 2, 2018, to $143.48 on September 7, 2018.
Tandem Diabetes Care: Stock Still Soaring after Q2 2018 Results
On August 2, Tandem Diabetes Care (TNDM) stock closed at $31.39. That’s a 9.87% rise from its prior day’s close of $28.57.
How the Freestyle Libre CGM Opportunity Is Playing Out for ABT
Abbott Laboratories stated during its second-quarter earnings release that it’s on track for achieving its fiscal 2018 guidance for Libre.
Why Senseonics Holdings Is Up ~5.6% Today
Today, Senseonics Holdings (SENS) is trading higher than yesterday’s close of $4.43 per share. The stock was up ~5% in premarket trading and is trending higher since then.
Tandem Diabetes Care’s International Expansion Strategy
Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.
Tandem Diabetes Care’s Stock Performance This Month
On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump.
MDT’s Diabetes Business Could Significantly Boost Its Revenue
In fiscal Q4 2018, Medtronic’s (MDT) Diabetes segment generated revenue of $645 million compared to $512 million in fiscal 2017.
What to Expect from Tandem’s Product Pipeline
T:sport is Tandem’s next-generation hardware platform, which is expected to reduce the size of the t:slim pump by 50%.
Tandem Diabetes Care Rallies on FDA Approval of Insulin Pump
Today, Tandem Diabetes Care (TNDM) opened~16.2% higher than yesterday’s closing price of $20.31, triggered by the news of FDA approval of its t:slim X2 insulin pump with Basal IQ technology.
Analysts’ Views on Tandem Diabetes Care after Its FDA Approval
After the market closed on June 21, Tandem Diabetes Care (TNDM) announced the FDA’s approval of its t:slim X2 insulin pump.
Johnson & Johnson Accepts Sale of Its LifeScan Business
On June 12, Johnson & Johnson (JNJ) announced it had accepted a $2.1 billion offer for the sale of its LifeScan business, which manufactures blood glucose monitoring devices and OneTouch products, from private equity company Platinum Equity.
Guardian Connect Expected to Be Medtronic’s Big Opportunity
On March 12, Medtronic announced that it has received FDA approval for its stand-alone continuous glucose monitoring system Guardian Connect.
Abbott’s Freestyle Libre CGM’s Performance, Growth Prospects
According to Abbott Laboratories, around two-thirds of diabetes patients have Type-1 diabetes while the rest have Type-2 diabetes.
Why Dexcom Stock Rose 6.8% Last Week
Dexcom (DXCM) rose 6.8% in the week ended March 29, 2018, to close at $74.20.
FDA Approves Arm Indication for Medtronic’s Guardian Sensor 3
On February 26, 2018, Medtronic (MDT) announced that the FDA has approved a new arm indication for its Guardian Sensor 3.
Medtronic Strengthens Diabetes Business with MiniMed Infusion Set
On February 21, 2018, Medtronic (MDT) announced the launch of its MiniMed Mio Advance infusion set.
Why Abbott Laboratories’ Product Pipeline Is Expected to Boost 2018
R&D and product pipeline In fiscal 4Q17, Abbott Laboratories(ABT) invested ~6.9% of its total sales in R&D (research and development). In fiscal 2018, the company plans to invest ~7.5% of its total sales. Abbott Laboratories launched more than 20 new products in fiscal 2017. Abbott Laboratories now has an attractive product pipeline, boosted by the recent […]
What’s the Outlook for Medtronic’s Segments in Fiscal 2018?
During the company’s 2Q18 earnings release on November 21, 2017, Medtronic (MDT) provided guidance for the full fiscal 2018.
Assessing the Role of Freestyle Libre in Abbott’s Diabetes Segment Growth
Abbott Laboratories (ABT) registered Diabetes sales of ~$373 million in 3Q17, which represented ~14.4% of its total Medical Devices segment sales.
Abbott’s Breakthrough CGM Device Freestyle Libre Wins FDA Approval
On September 27, Abbott Laboratories (ABT) announced the FDA approval of its Flash CGM (continuous glucose monitoring) device, Freestyle Libre.
Abbott Gets UK Reimbursement Approval for Freestyle Libre
On September 13, 2017, Abbott Laboratories (ABT) announced the reimbursement approval of its Freestyle Libre system.
Behind Johnson & Johnson’s Recent Medical Device Launches
JNJ’s new product launches, acquisitions, and collaborations contributed significantly to its Medical Devices segment’s sales.
Abbott’s Freestyle Libre Gets Reimbursement Approval in France
Abbott Laboratories’ (ABT) Freestyle Libre is a sensor-based continuous glucose monitoring system that monitors and evaluates glucose levels up to 14 days.
Diabetes Management Breakthrough: Medtronic’s MiniMed 670G
On June 7, 2017, Medtronic (MDT) announced the launch of MiniMed 670G—the world’s first HCL (hybrid closed loop) insulin delivery system.
Company & Industry Overviews What Explains the Columbia Select Large Cap Growth Fund’s Poor Showing?
The short-term performance of the Columbia Select Large Cap Growth Fund – Class A (ELGAX) is excellent, and the past six months have been great for the fund.
Johnson & Johnson’s Latest Medical Device Launches
Johnson & Johnson has announced the schedule for the launch of the OneTouch Via insulin patch. It plans to launch the device in select US markets by the end of 2016.
Medtronic’s Initiative to Advance Type 2 Diabetes Device Business
Medtronic (MDT) has partnered with Qualcomm to develop a disposable continuous glucose monitor (or CGM) for the type 2 diabetes patient population.
Dexcom Tanks on Profit Booking after Directors Increase Stakes
Dexcom (DXCM) was the worst-performing stock within the iShares U.S. Medical Devices ETF (IHI) on May 26, 2016.
IHI Remained Flat, Hovering Around Its 52-Week High
The Markets fell silent and remained flat on April 14, 2016. The iShares US Medical Devices (IHI) closed flat with no gains and no losses for the day.
The iShares US Medical Devices ETF (IHI) Has Put Nothing under the Tree in December—Yet
The iShares US Medical Devices ETF (IHI) rose by 1.15% on December 15, closing at $122.32, 2% higher than its 100-day moving average price of $119.8.
